N
NodThera
Biotech & Life Sciences · Montrose, United Kingdom · Founded 2016
Small molecule drug candidate to treat inflammatory diseases, as well as other drugs for neurodegenerative diseases and cancers MoreLess
NodThera is a biotechnology company focused on developing innovative therapeutics targeting the NLRP3 inflammasome, a protein complex involved in the body's inflammatory response. The company operates in the pharmaceutical and healthcare market, serving patients suffering from chronic inflammatory diseases. NodThera's business model revolves around its proprietary drug discovery platform, which leverages advanced medicinal chemistry to create next-generation small molecule inhibitors. These inhibitors are designed for high potency, optimal pharmacokinetics (how the drug moves through the body), and effective tissue penetration. The company generates revenue through the development and potential commercialization of its drug candidates, as well as through partnerships and collaborations with other pharmaceutical companies. NodThera's lead candidate, NT 0167, is currently in Phase 1 clinical trials, assessing its safety and efficacy. The company is also progressing a pipeline of other NLRP3 inhibitors, including those capable of crossing the blood-brain barrier to treat neurological conditions.
Keywords: NLRP3 inflammasome, chronic diseases, drug discovery, small molecules, biotechnology, pharmacokinetics, Phase 1 clinical trial, medicinal chemistry, inflammation, neurological conditions.
Company overview
NodThera company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2016
- Headquarters
- Montrose, United Kingdom
- Employees
- 23
- Open positions
- 1
- Dealroom signal
- 69.5
Valuation & funding
NodThera funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Oct 2021 | $0 | — | Undisclosed | ↗ |
| SERIES BOther financing | Jun 2020 | $59M | $165M | Cowen Group · Epidarex Capital · F-Prime · Sanofi Ventures | — |
| SERIES AOther financing | Jun 2018 | $35M | $141M | Sofinnova Partners · Epidarex Capital · F-Prime · 5AM Ventures | ↗ |
| EARLY VCOther financing | Dec 2017 | $475K | $1.9M | Undisclosed | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | EBITDA | Margin |
|---|---|---|
| 2026 | −$24M | — |
| 2025 | −$24M | — |
| 2024 | −$24M | — |
| 2023 | −$24M | — |
| 2022 | −$24M | — |
| 2021 | −$28M | — |
| 2020 | −$22M | — |
Growth signals
NodThera website traffic
Latest recorded traffic for NodThera is 3.7K monthly website visits, up 306.6% over the last three months. NodThera's team grew 4.5% over the past year.
Comparisons
NodThera compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
NodThera's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where NodThera has talent and traffic
In the news
Latest news about NodThera
Recent press, funding announcements, and product moves mentioning NodThera — open to read from the original sources.
Market sentiment
What the market is saying about NodThera
An AI-synthesized read of the highest-engagement posts about NodThera on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NodThera’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.